Clinical Trial Update: Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating neoadjuvant and adjuvant tislelizumab in nasopharyngeal carcinoma is active/not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING